Semaglutide reduces weight, improves cardiometabolic parameters for older adults

Once-weekly injectable semaglutide 2.4 mg was linked to reductions in body weight and improvements in multiple cardiometabolic parameters for older adults with obesity, according to a pooled analysis of the STEP trials. “Older adults represent, in many countries, the age group with the higher prevalence of obesity and related complications,” Luca Busetto, PhD, professor in nutrition and dietetic